Literature DB >> 25535102

Electroporation for therapeutic DNA vaccination in patients.

Matti Sällberg1, Lars Frelin, Gustaf Ahlén, Margaret Sällberg-Chen.   

Abstract

DNA vaccination has historically failed to raise strong immune responses in humans. Recent delivery techniques such as the gene gun and in vivo electroporation (EP)/electrotransfer (ET) have completely changed the efficiency of DNA vaccines in humans. In vivo EP exerts multiple effects that contribute to its efficiency. The two central factors are most likely the increased DNA uptake due to the transient membrane destabilization, and the local tissue damage acting as an adjuvant. To date, several studies in humans have used in vivo EP/ET to deliver DNA. Some of these results have been quite promising with strong T cell responses and/or transient effects on the viral replication. This suggests that improved strategies of in vivo EP/ET can be a future way to deliver DNA in humans.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25535102     DOI： 10.1007/s00430-014-0384-8

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN： 0300-8584            Impact factor:   3.402


  24 in total

1.  The danger model: a renewed sense of self.

Authors:  Polly Matzinger
Journal:  Science       Date:  2002-04-12       Impact factor: 47.728

2.  In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells.

Authors:  Gustaf Ahlén; Jonas Söderholm; Torunn Tjelle; Rune Kjeken; Lars Frelin; Urban Höglund; Pontus Blomberg; Michael Fons; Iacob Mathiesen; Matti Sällberg
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

Review 3.  The control of adaptive immune responses by the innate immune system.

Authors:  Dominik Schenten; Ruslan Medzhitov
Journal:  Adv Immunol       Date:  2011       Impact factor: 3.543

4.  DNA electroporation of multi-agent vaccines conferring protection against select agent challenge: TriGrid delivery system.

Authors:  Andrea M Keane-Myers; Matt Bell; Drew Hannaman; Mark Albrecht
Journal:  Methods Mol Biol       Date:  2014

5.  Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trial.

Authors:  M Belehradek; C Domenge; B Luboinski; S Orlowski; J Belehradek; L M Mir
Journal:  Cancer       Date:  1993-12-15       Impact factor: 6.860

6.  Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.

Authors:  R Wang; D L Doolan; T P Le; R C Hedstrom; K M Coonan; Y Charoenvit; T R Jones; P Hobart; M Margalith; J Ng; W R Weiss; M Sedegah; C de Taisne; J A Norman; S L Hoffman
Journal:  Science       Date:  1998-10-16       Impact factor: 47.728

7.  Heterologous protection against influenza by injection of DNA encoding a viral protein.

Authors:  J B Ulmer; J J Donnelly; S E Parker; G H Rhodes; P L Felgner; V J Dwarki; S H Gromkowski; R R Deck; C M DeWitt; A Friedman
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

8.  Gene transfer into muscle by electroporation in vivo.

Authors:  H Aihara; J Miyazaki
Journal:  Nat Biotechnol       Date:  1998-09       Impact factor: 54.908

9.  Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.

Authors:  Spyros A Kalams; Scott D Parker; Marnie Elizaga; Barbara Metch; Srilatha Edupuganti; John Hural; Stephen De Rosa; Donald K Carter; Kyle Rybczyk; Ian Frank; Jonathan Fuchs; Beryl Koblin; Denny H Kim; Patrice Joseph; Michael C Keefer; Lindsey R Baden; John Eldridge; Jean Boyer; Adam Sherwat; Massimo Cardinali; Mary Allen; Michael Pensiero; Chris Butler; Amir S Khan; Jian Yan; Niranjan Y Sardesai; James G Kublin; David B Weiner
Journal:  J Infect Dis       Date:  2013-07-08       Impact factor: 5.226

10.  In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers.

Authors:  Sandhya Vasan; Arlene Hurley; Sarah J Schlesinger; Drew Hannaman; David F Gardiner; Daniel P Dugin; Mar Boente-Carrera; Roselle Vittorino; Marina Caskey; Johanne Andersen; Yaoxing Huang; Josephine H Cox; Tony Tarragona-Fiol; Dilbinder K Gill; Hannah Cheeseman; Lorna Clark; Len Dally; Carol Smith; Claudia Schmidt; Harriet H Park; Jakub T Kopycinski; Jill Gilmour; Patricia Fast; Robert Bernard; David D Ho
Journal:  PLoS One       Date:  2011-05-16       Impact factor: 3.240
View more
  5 in total

Review 1.  DNA-launched live-attenuated vaccines for biodefense applications.

Authors:  Peter Pushko; Igor S Lukashevich; Scott C Weaver; Irina Tretyakova
Journal:  Expert Rev Vaccines       Date:  2016-04-25       Impact factor: 5.217

Review 2.  Vaccine and Therapeutic Options To Control Chikungunya Virus.

Authors:  Ann M Powers
Journal:  Clin Microbiol Rev       Date:  2017-12-13       Impact factor: 26.132

3.  A phase 1, randomized, controlled dose-escalation study of EP-1300 polyepitope DNA vaccine against Plasmodium falciparum malaria administered via electroporation.

Authors:  Paul Spearman; Mark Mulligan; Evan J Anderson; Andi L Shane; Kathy Stephens; Theda Gibson; Brooke Hartwell; Drew Hannaman; Nora L Watson; Karnail Singh
Journal:  Vaccine       Date:  2016-09-30       Impact factor: 3.641

4.  Coinjection of IL2 DNA enhances E7-specific antitumor immunity elicited by intravaginal therapeutic HPV DNA vaccination with electroporation.

Authors:  Y Sun; S Peng; A Yang; E Farmer; T-C Wu; C-F Hung
Journal:  Gene Ther       Date:  2017-05-11       Impact factor: 5.250

Review 5.  A Comprehensive Review of Calcium Electroporation -A Novel Cancer Treatment Modality.

Authors:  Stine K Frandsen; Mille Vissing; Julie Gehl
Journal:  Cancers (Basel)       Date:  2020-01-25       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.